The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2021 | Venetoclax and 5-azacytidine for the treatment of MDS and CMML
Alexandre Bazinet, MD, McGill University, Montreal, Canada, presents findings from a Phase I/II study (NCT04160052) of venetoclax and 5-azacytidine, a hypomethylating agent (HMA), in patients with relapsed/refractory myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML). HMA monotherapy currently represents the standard of care in these groups of patients but durability of response rates remain low. Patients who are treatment naïve or progressed on HMAs were recruited, with the primary outcomes being safety, tolerability, and overall response rate (ORR). Whilst the regimen was generally well tolerated and there were high response rates across the cohort, cases of myelosuppression hindered recovery. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
